Avinger Closes $4.5 Million Equity Offering
August 26 2019 - 4:02PM
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative
treatments for Peripheral Artery Disease (PAD
)
today announced the closing of an underwritten public offering of
3,813,559 shares of its common stock at a price of $1.18 per share,
for total gross proceeds of approximately $4.5 million, before
deducting underwriting discounts, commissions and other offering
expenses payable by the Company. Additionally, the Company has
granted the underwriters a 45-day option to purchase up to 572,033
additional shares to cover over-allotments, if
any
. The shares were offered pursuant to a shelf
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (SEC). A prospectus
supplement and accompanying base prospectus relating to the
offering were filed with the SEC and are available on the SEC’s
website at www.sec.gov.
A copy of the prospectus supplement and accompanying base
prospectus relating to the offering may be obtained by contacting
Aegis Capital Corp., Attention: Prospectus Department, 810
7th Avenue, 18th floor, New York, NY 10019, by email
at prospectus@aegiscap.com, or by telephone at (212)
813-1010.This press release does not and shall not constitute an
offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction. Any
offer, if at all, will be made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective
registration statement.
About Avinger, Inc.Avinger is a
commercial-stage medical device company that designs and develops
the first-ever image-guided, catheter-based system that diagnoses
and treats patients with peripheral artery disease (PAD). Avinger
is dedicated to radically changing the way vascular disease is
treated through its Lumivascular platform, which currently consists
of the Lightbox imaging console, the Ocelot family of chronic total
occlusion (CTO) catheters, and the Pantheris® family of atherectomy
devices. Avinger is based in Redwood City, California. For more
information, please visit www.avinger.com.
Forward-Looking StatementsThis press release
includes statements that constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are based on management’s current expectations and are
subject to risks and uncertainties that are often difficult to
predict, are beyond the company’s control, and which may cause
results to differ materially from expectations. Accordingly,
investors should not to place undue reliance on these
forward-looking statements, which are based on our expectations as
of the date of this press release and speak only as of the date of
this press release. For a discussion of the most significant risks
and uncertainties associated with Avinger’s business, investors are
urged to review the company’s filings with the Securities and
Exchange Commission. Except as required by law, the Company
undertakes no duty to update any forward-looking statement made
herein, whether as a result of new information, future events or
otherwise.
Public Relations Contact:Phil PreussVP of
Marketing & Business OperationsAvinger, Inc.(650)
241-7942pr@avinger.com
Investor Contact:Mark WeinswigChief Financial
OfficerAvinger, Inc.(650) 241-7916ir@avinger.com
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Sep 2023 to Sep 2024